Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Request Technical & Commercial Info: Obtain the product catalog, strengths, packaging options, MOQ, lead times, and stability summaries
Retatrutide's triple receptor agonism offers complementary metabolic effects through simultaneous GLP-1, GIP, and GCG pathway activation, studied for synergistic metabolic regulation, glucose homeostasis, and weight management research.nnMechanisms: Enhanced insulin secretion, improved glucose utilization, reduced appetite signaling, increased energy expenditure, and metabolic adaptation through three hormone pathways.nnProduct Specifications: GLP-3RT Retatrutide 10mg lyophilized | 99% purity HPLC verified | Storage -20C lyophilized, 2-8C reconstituted | COA includednnResearch applications: Metabolic disease modeling, dose-response studies, glucose control pathways, weight regulation mechanisms, multi-receptor GLP/GIP/GCG activation, and metabolic syndrome reversal investigation
Cagrilintide (Long-Acting Amylin Analog) Amino acid sequence modified from native human amylin [3] Fatty acid acylation extends half-life to approximately 7 days [2] Selective amylin receptor agonist (AMY1, AMY2, AMY3) [4] Delays gastric emptying and reduces food intake [5] Controls postprandial glucose metabolism [6] Synergistic effects with GLP-1 receptor agonists [7] CagriSema: The Synergistic Combination One of the most significant developments in cagrilintide research is its combination with semaglutide (a GLP-1 receptor agonist), known as CagriSema
berberine is contraindicated in pregnancy and breastfeeding
In vitro experiments were performed after 48 h and 7 days of doxy treatment
